Leadership team & experts.

As Head of Innovation and Product Development at Inizio Ignite, STEM, Adam drives the design and implementation of future solutions. He helps life sciences clients leverage data-driven, AI-powered insights to boost brand performance and patient outcomes. Adam has over 25 years experience within the pharmaceutical industry, including 16 years working within several Top 20 pharmaceutical companies, in sales, market access, digital innovation and marketing positions. Adam joined STEM in 2017, and before his current role, lead the global client relations team and has extensive experience of solving complex client challenges and delivering excellence at both a global and local level.

Aidan has extensive experience advising biopharmaceutical clients across Inizio Ignite, Putnam’s Value, Pricing & Access Strategy and Commercial Strategy practice areas. His core focus areas include but are not limited to commercial opportunity sizing/assessment, pricing and contracting, LOE planning/lifecycle management, evidence generation and clinical trial design, distribution, and value proposition. To date, Aidan has overseen or managed day-to-day execution of >50 projects ranging in size and scope. His expertise spans the US and global markets and includes branded and biosimilar products as well as treatment modalities. Recent therapeutic area experience includes solid and liquid tumors, autoimmune conditions, rare diseases (e.g., sickle cell disease, transfusion-dependent thalassemia, and orphan epilepsy), and vaccine-preventable disease. Aidan earned his BA in Neuroscience with distinction from Colgate University, where he contributed to research regarding an animal model of autism spectrum disorder (ASD) in songbirds. Before joining Putnam in 2021, Aidan worked at another life sciences consulting firm focused primarily on Value, Pricing, & Access.

Alex’s practice focuses on advising clients at the intersection of transformative pharmacology, cutting edge commercial strategy, and Value, Pricing, and Access (VPA) excellence. Alex works with global and start-up pharmaceutical and biotechnology companies on pre-launch and in-line strategy development in key global pharma markets. Recent therapeutic area experience includes small molecule and biopharma approaches to heme and solid tumor oncology, immunological / inflammatory diseases, and extensive work in vaccine preventable diseases. Alex joined Putnam in 2013 after receiving his Ph.D. in Experimental and Molecular Medicine from Dartmouth (focused in new drug targets to treat lung cancer) subsequent to a B.S. in Bioinformatics and Molecular Biology from Rensselaer Polytechnic Institute.

Alison Paymer is an Executive and Managing Director at Inizio Ignite where she leads the Organizational Effectiveness practice. She brings over 25 years of experience in the healthcare sector, spanning both health care provider and pharmaceutical clients. Alison specializes in helping organizations translate strategy into execution by designing operating models and organizational structures that enable performance at scale. She has led large, complex transformations for industry-leading companies, with a focus on aligning priorities, clarifying accountabilities, and embedding ways of working that drive measurable and sustained impact. In addition to her advisory work, Alison is a Leadership and Executive Coach to senior leaders partnering with them to navigate complexity, strengthen leadership effectiveness, and lead through periods of significant change.

Alison Thompson leads Strategic Enablement for Innovation & Growth at Inizio Ignite, driving alignment, execution, and transformation across the Advisory business. She partners with senior leadership to define priorities, connect efforts across practices and innovation teams, and translate strategy into measurable outcomes. With more than 15 years of experience across life sciences, healthcare, and consulting, Alison specializes in turning strategy into action—structuring complex challenges, leading cross-functional programs, and embedding effective ways of working. Known for simplifying complexity and engaging stakeholders, Alison fosters collaboration and continuous improvement to advance business performance. After graduating from Penn State, Alison began her career in advertising before transitioning to consulting with Accenture and Vynamic.

Aman brings 15+ years of experience delivering data science and ML solutions across fintech, insurance analytics, retail, and e-commerce. He leads data science teams and the development of Navigator AI™. He previously built data-driven platforms including credit scoring engines.

Andrew is a market insights expert with over 25 years of experience helping clients answer their most critical business questions and drive smarter decisions. He specialises in turning complex data into clear, actionable insight that fuels growth and competitive advantage. With deep expertise across the full product lifecycle, Andrew supports organisations from early opportunity assessment and go-to-market strategy through to brand optimisation and lifecycle management. Known for his pragmatic, insight-led approach, Andrew partners with clients to deliver strategies that create real, measurable impact.

Ashley Stanley is an Executive and Managing Director in Inizio Ignite, Vynamic’s Product Launch Practice and is a leader in pharmaceutical launch strategy and execution. With 15+ years of experience in Life Sciences, she has supported complex product launches across both U.S. and global markets, with a particular focus on emerging biotech organizations navigating first launches and scaling capabilities. Ashley partners with clients from early planning through post-launch, designing and implementing fit-for-purpose launch frameworks, governance structures, and cross-functional ways of working that drive readiness and sustained performance. She brings deep expertise across a range of launch scenarios, bridging strategy and execution to enable seamless, high-impact product launches.

Ben serves as a strategic leader in value, access and pricing strategy across US and global markets. Ben has a notable breadth of experience with US and global launch pricing and provider, payer contracting strategy engagements helping to inform client decision-making across a range of therapeutic areas. Recent therapeutic area experiences includes both heme and solid tumor oncology, immunology, and rare diseases. Ben joined Putnam in 2020 after receiving his Masters in Biomedical Engineering from Duke University. Ben also holds a BS in Biomedical Engineering from Bucknell University.

Ben is Head of Delivery Enablement at Inizio Ignite, where he leads the development and scaling of Inizio Ignite’s Global Delivery Hub model, with a core focus on expanding and strengthening the organisation’s India capability. He works closely with senior leadership to shape a global operating model that enables consistent, scalable, and high-quality delivery across Ignite and the wider Inizio network. Ben brings over 15 years of international leadership experience across healthcare and life sciences, including senior roles within Inizio at STEM Healthcare. He has extensive experience across APAC and Africa, having led regional business units spanning, South Africa, ASEAN, Australia, and New Zealand, with responsibility for growth strategy, commercial performance, and operational execution across diverse markets. Prior to this, Ben held executive leadership roles at Bausch & Lomb nad Bausch Health, including General Manager for UK Pharma and European Commercial Operations. He holds an MSc in Logistics and Supply Chain Management from Cranfield School of Management. His core areas of focus include delivery operations, organisational effectiveness, and enabling sustainable growth through execution excellence.

Brian Stamm is an Executive and Managing Director in Inizio Ignite, Vynamic’s Product Launch Practice with over 10 years of experience supporting pharmaceutical and biotech companies across oncology, rare disease, and other key therapeutic areas. He specializes in operationalizing strategy into execution designing launch playbooks, governance models, and operating frameworks that enable cross-functional teams to align, adapt, and deliver successful launches.

Catriona leads the health economic modelling team at Inizio Ignite, Putnam. She joined the team in November 2022, having previously worked at Lumanity (formerly known as BresMed) as a Principal Health Economist, and prior to this, as a research fellow at HERG, Brunel University. Her core focus of interest is the development of health economic models for global and Health Technology Assessment purposes. She has worked across a wide range of disease areas, including oncology, chronic, and rare diseases. Catriona has published cost-effectiveness studies in areas including cardiovascular, refractory epilepsies, and liver disease. She also has an interest in expert elicitation methods, in particular, the use of structured expert elicitation to address data gap challenges.

Chloe Stockwell-Clark is Vice President of Product at Inizio Ignite, STEM, leading AI-powered capabilities that enhance value for global biopharma partners. She drives an intelligent, data-led insights ecosystem, bringing scientific rigor, product strategy, and innovation to real-world healthcare challenges.

Christina Nikolos is a Practice Delivery Lead in Inizio Ignite, Vynamic's Product Launch practice, where she drives the strategy and execution of complex product launches across life sciences organizations. She has supported global and U.S. launches in oncology, hematology, and rare disease, with a specialization in leading alliance launches and navigating agile team environments. Earlier in her career, she led orthopedic medical device and biomaterial launches. Christina specializes in early launch planning, operational readiness, and execution, partnering with brand teams and leading cross-functional workstreams to drive alignment and results. She is known for her collaborative, people-focused approach and ability to connect detailed execution with broader strategy.

Clement co leads Inizio Ignite, Putnam’s HTA and Market Access team, advising biopharma companies from early asset planning through launch. He brings deep expertise in HEOR, HTA, and market access, with particular strength in European payer and HTA strategy. His recent thought leadership includes EU HTA and Joint Clinical Assessment. Clement holds an MSc in Health Economics and a PhD in Health Sciences, has authored more than 200 publications and conference presentations, is an Associate Researcher at Aix-Marseille University and co-editor of the Journal of Medical Economics

Craig Galloway leads Inizio Ignite, STEM's Global Client Partnership teams - delivering performance boosting insights for above country pharmaceutical leaders.

Daisaburo serves as President and Representative Director of Inizio Ignite, STEM Japan and a member of its global leadership team. Since joining in 2019, he has led the transformation and expansion of STEM Japan, fostering a deeply client-centric mindset and building an organization capable of addressing a wide range of client needs—combining strategic alignment, execution excellence, and integrated solutions that drive measurable impact on client performance. As a hands-on consultant, he has personally led over 300 projects across commercial and medical strategy as well as organizational transformation. He brings 24 years of global pharmaceutical experience. Prior to STEM, he was Head of the Neuroscience Business Unit at Biogen, where he tripled business performance in 4 years. He also held leadership roles at Bayer. He holds a law degree from Ryukoku University, an MBA from the University of Toronto, and an MSc from Henley Business School. He is also the author of 'The MR Playbook'.

Dani is the chief operation officer for Inizio Ignite, STEM and Research Partnership. Dani has over 25 years of experience in Pharma market research and previously led the US international research team at Adelph Research and started the US arm of Branding Science. She joined STEM as COO in July 2024 and took on an expanded role to include RP in Jan 2026. Dani has a passion for qual and is an expert moderator with specific expertise in liquid tumors and rare disease. She holds a PhD in molecular genetics and a BSc in Biochemistry and Molecular Biology and prides herself in being able to combine complex science with a commercial lens. In her COO role she has responsibility for driving best practices that create optimal customer experiences, ensuring global consistency cross delivery teams and is responsible for overseeing the operating model for STEM AI.

Dennis is a Senior Director at Inizio Ignite, Vynamic with over 20 years of experience helping life sciences organizations successfully bring therapies to market and scale commercial operations. He specializes in launch readiness, strategic planning, and digital transformation, with deep expertise across rare disease, cell and gene therapy, and oncology. Dennis has led complex global launch programs, including first-to-market therapies, where he has driven cross-functional alignment, defined readiness KPIs, and built scalable playbooks for execution. He has also led large-scale digital customer engagement initiatives across global markets, deploying platforms such as Veeva and Adobe Experience Manager. Additionally, Dennis has partnered with patient services teams to design end-to-end patient journeys and operating models. Prior to Vynamic, he held roles at Veeva Systems and Slalom Consulting. He holds an MBA from Suffolk University and a BA in Business from Assumption University

Don specializes in helping life sciences organizations translate strategy into execution, with a focus in commercial functions. He brings over 15 years of experience advising more than 20 life sciences companies, ranging from emerging biotechs to top 10 pharma. Don has deep expertise supporting companies as they transition from pre-commercial to commercial, including go-to-market strategy, commercial model design, and building the organizational capabilities required to successfully launch a first product. In his role, he manages key client accounts, overseeing multiple high-impact engagements simultaneously while leading teams, ensuring delivery excellence, and deepening senior client relationships. Prior to Vynamic, Don spent five years in PwC's life sciences advisory practice, leading engagements across functions and geographies before focusing on US commercial strategy and execution. He holds an MBA from Carnegie Mellon University’s Tepper School of Business and a BS in Economics from Trinity College.

Eileen Smith is an Executive and Delivery Lead in Inizio Ignite, Vynamic’s Organizational Effectiveness practice. She partners with health and life sciences organizations to design and deliver transformations of varying scale and scope, aligning strategy, operating models, and ways of working to drive sustainable performance. With nearly two decades of consulting experience, Eileen brings deep expertise supporting clients from emerging biotech to large, global pharmaceutical organizations as they navigate complex change.

Eric leads Inizio Ignite, Putnam’s Value, Pricing & Access global practice, consisting of a deep team of market access strategy, HEOR and RWE professionals situated across 10 global offices in addition to satalite locations. Prior to Putnam joining Inizio, Eric was Putnam’s Partnership Chair, coordinating firm strategy and governance. In 30 years with Putnam, Eric has built deep expertise in market access strategy and supporting clients in navigating challenging payer, healthcare system, and competitive environments. He has supported clients across a wide range of therapeutic areas, modalities, and healthcare system sectors, with much of his work helping clients to pioneer new areas.

Eric Faulkner is a globally recognized executive in innovative technology evidence development, value demonstration, access and commercialization with >25 years of experience. Most recently he has recently, he has served as President of Passage Health Associates, Chief Scientific Officer of SymetryML a breakthrough AI/ML data sharing platform, and Vice President and Exec Value and Access Team at Novartis Gene Therapies supporting the world’s leading gene therapy scale to >$2B spanning 55+ markets. Experience includes co-founding a top 5 RWE function for a leading CRO and multiple cross-function Centers of Excellence in emerging biopharma and device technology growth areas for IQVIA and Thermofisher/PPD. Mr. Faulkner is a recognized global thought leader in emerging technology evidence development, product access and patient/health system uptake, including >750 strategic peri- and post-approval scenarios. Eric has helped companies navigate multiple 1st in the world product market access and commercial scenarios with limited or no global precedent.

Eric Wood is a Senior Executive at Inizio Ignite, Vynamic, responsible for leading core practice areas of Product Launch, Customer Experience, and Organization Effectiveness. As Head of Commercial, he is focused on refining and deepening Vynamic's core offerings, improving our delivery model to meet evolving client needs, and driving collaboration across Inizio Ignite to elevate our capabilities. Eric has been with Vynamic for more than 11 years, serving in a variety of roles from consulting delivery and various levels of Account Leadership. He has nearly 20 years' life sciences consulting experience helping clients navigate complex challenges in R&D, Medical, and Commercial.

Erika works with pharmaceutical and biotech clients to develop strategies for pipeline agents, evaluate commercial opportunities, and provide strategic guidance on a broad set of access-related topics. She has worked across a wide range of therapeutic areas including oncology, vaccine-preventable diseases, immunology, neurology, and rare diseases. Erika brings experience in indication prioritization assessments, clinical development strategy, strategic evidence planning, and evaluating market opportunities using qualitative and quantitative methodologies. Prior to joining Putnam in 2019, Erika earned her Ph.D. in Biological Sciences at Harvard University and Sc.M. from the Johns Hopkins Bloomberg School of Public Health.

Eros has almost 20 years of research design and analysis experience; the last 15 years have been focused on health outcomes and real-world data analysis using administrative data. He has led a wide array of real-world projects and has deep experience with retrospective studies using both claims and EHR databases, prospective research, patient reported outcomes, and phase IV trials. Eros has worked in academia, industry, and in consultancy. He has experience designing research from both the manufacturer and the payer perspectives and has presented at international conferences as well as written multiple peer-reviewed publications. He has a master’s degree in experimental psychology from DePaul University in Chicago.

Since joining Putnam in 2017, Ethan has advised clients on a variety of business needs including pricing and market access strategy, commercial opportunity assessment, competitor strategic simulation, operational model development, and supply and demand forecasting. A core focus of Ethan’s work has been within the Value, Pricing & Access strategy practice area, where he has supported global pharmaceutical and biotech clients across both US and international markets. Ethan has extensive experience in developing access strategies at all stages of the product lifecycle, from launch access strategy through loss of exclusivity strategy. He has covered a broad range of therapeutic areas, with a particular focus on inflammation and immunology, rare disease (in particular, hematologic and cardiac), vaccines, and oncology (in particular, cell therapy). Before Putnam, Ethan earned a B.S. in Biology and B.A. in Economics from Boston College.

Hugo’s work focuses on the Value, Pricing & Access strategy practice area, specializing in generation of pricing and contracting strategies for pharmaceutical and biotech clients across both US and international markets. He has extensive experience in developing access strategies for therapies in both inpatient and outpatient settings, at all stages of the product lifecycle. Recent projects have covered a range of therapeutic areas including inflammation and immunology, rare diseases, and vaccines. Hugo joined the Putnam London office at its inception in 2020. Prior to joining Putnam, he worked for Monitor Deloitte, focusing on healthcare strategy across a broad range of public and private sector clients. Hugo holds a BA in Philosophy, Politics and Economics from the University of Oxford.

James Linney is a Senior Director in the Global Client Partnerships team at Inizio Ignite, STEM, where he leads global programmes in partnership with pharmaceutical clients. He works with global and regional stakeholders to coordinate multi-market projects, supporting key brands and business priorities by assessing strategic alignment and how this translates into field execution across commercial, medical, and market access teams. With nearly five years at STEM, across both local and global roles, James brings over 18 years of experience in the pharmaceutical and life sciences industry, including extensive experience in product launches. His background includes senior marketing and commercial roles across multiple therapy areas, with a focus on brand strategy, customer engagement, and driving performance through effective execution.

Jane Barrett is President, APAC at Inizio Ignite, STEM, where she leads regional strategy and growth across Asia-Pacific. She brings deep expertise in pharmaceutical consulting, with a focus on commercial effectiveness, including sales force optimisation, brand strategy, and go-to-market execution. At STEM Healthcare, Jane partners with clients to embed data-driven decision-making and improve performance through analytics-led insights. She works with global and regional organisations to navigate complex markets and drive sustainable growth. Jane is committed to building high-performing teams and helping clients deliver better outcomes for patients in a rapidly evolving healthcare landscape.

Jason Caine is an Executive at Inizio Ignite, Vynamic, and a leader within the firm’s Customer Experience practice. He specializes in customer experience, marketing and omnichannel strategy, and change management. He brings a strong digital and cross-industry perspective, helping healthcare and life sciences organizations modernize how they engage customers and execute commercially. Jason partners with senior leaders to shape strategy, design operating models, and lead complex transformations. His experience spans patient and HCP engagement, business readiness, and program leadership, with a focus on translating vision into practical, scalable action. He has led cross-functional initiatives supporting product launches, digital capability builds, and large-scale organizational change. Prior to joining Vynamic, Jason held roles at PwC and Kantar, where he developed a strong foundation in consumer brand strategy and marketing.

Jen is a senior director for Inizio Ignite, Vynamic, splitting her time between delivering high impact consulting projects for her Life Sciences clients and driving strategic inititives for the Vynamic business. She completed her undergrad at the University of Notre Dame (BS, Biology & Psychology) and her graduate degree (MBA) at Temple University. Wth more than a decade of experience partnering with Life Sciences clients, her core areas of focus include strategic transformation, launch excellence, and global launch.

Jeremy Smith leads Inizio Ignite, Research Partnership's US business, overseeing the firm's growth, client partnerships, and team across North America as part of the Inizio network. He brings over two decades of experience as a trusted advisor to pharmaceutical and biotechnology leaders, with deep expertise spanning oncology, rare disease, and broader therapeutic areas across the full product lifecycle, from early asset development through launch and long-term portfolio strategy. Before joining Research Partnership, Jeremy held senior executive roles at a leading healthcare consultancy, where he built and led global client partnerships with some of the industry's largest organizations. He is known for building high-performing teams grounded in curiosity, accountability, and trust, and for leadership that raises expectations while giving people the confidence to meet them.

Jo Ann brings over 20 years of C-level strategy and operational experience in the Healthcare field specializing in digital technology and data-driven business transformation initiatives, including: global digital and data analytics centers of excellence, enterprise and business unit AI/GenAI value programs, tech/data productization, 360 HCP customer master ecosystems, medical affairs digital innovation, field effectiveness platforms, M&A, and strategic partnerships with data providers, Big Tech and emerging tech companies.

Joanna provides scientific and analytical insight into the development of business strategies for pharmaceutical and biotechnology clients. She has experience in competitive landscape and strategy assessments across the product life cycle and within emerging technologies (specifically within oncology, hematology, and rare diseases), indication prioritization for R&D strategy, market sizing and demand assessment for forecasting, product launch and pricing, and brand strategy development. Prior to joining Putnam, Joanna earned her Ph.D. from the UC Berkeley – UCSF Graduate Program in Bioengineering, completing her dissertation on the mechanobiology of growth factor receptor dynamics in chondrocytes. During that time, she also received a Management of Technology minor through the UC Berkeley Haas School of Business. She earned her BS in Biomedical Engineering, with a minor in Management, from the University of Minnesota, Twin Cities.

Joanne leads the European Value, Pricing & Access strategy practice at Inizio Ignite, Putnam, with 18 years’ experience in pricing and access. The focus of her work is advising biopharmaceutical clients from early phase asset planning, through to launch, and how to navigate complex payer and healthcare systems to ensure optimal patient access. Prior to joining Putnam, Joanne gained experience in developing and implementing Real World Evidence studies to support a broad range of applications, including evidence generation planning/implementation and innovative contracting. Joanne also has experience leading global cross-functional teams including medical, HEOR, commercial, access and R&D, across a broad range of therapeutic areas, including rare diseases, oncology, immunology, biomarker and companion diagnostic strategies. She has direct experience working as a payer within the UK market and remains close to key payer groups across European markets, supporting the evolution of key policies to enable patient access. She has strong links with NICE and NHS England and works with pan-European groups such as EUCOPE and EUnetHTA.

John has over 30 years of strategy consulting experience. He has counseled senior executives at numerous leading pharmaceutical and biotech companies, providing strategic support and recommendations on a wide array of issues including pricing, contracting and reimbursement strategies, corporate strategy, new product commercialization, clinical trial development, and sales force optimization strategies. John has extensive experience in specialty pharmaceutical markets that comprise CNS, oncology, immunology and inflammation, and rare disease. John has advised on dozens of product launch pricing strategy decisions including some of the most noteworthy product launches in the past five years. Prior to joining Putnam, he worked for an economics consulting firm. John has served on the Board of Directors for the National Tay-Sachs & Allied Diseases Association, Inc. and currently sits on the organization’s Corporate Advisory Council. John earned a BA in economics summa cum laude, Phi Beta Kappa from Tufts University and an MBA from Harvard Business School.

As part of Inizio Ignite, Putnam’s Portfolio, Licensing & Development practice, John helps clients build clinical development and go-to-market strategies. Across therapy areas, he has helped clients drive strategic prioritization decisions about where to position their early-stage assets in the future treatment paradigm, how to determine the target profile and clinical development path required to win and differentiate, and how to size the opportunity and weigh trade-offs. He joined SmartAnalyst (now part of Putnam) in 2003 and has partnered with biopharma clients in North America, Europe, and Asia-Pacific to provide data-driven strategies and insights that inform important clinical development and investment decisions. Prior to SmartAnalyst, he worked in healthcare communications, where he supported media relations for healthcare providers and biotech companies. He graduated summa cum laude from Columbia University.

Josh is a Practice Delivery Lead for the Customer Experience practice in Inizio Ignite. He helps life sciences clients build the strategies, operating models, and omnichannel capabilities needed to better engage HCPs, patients, and payors. With 17+ years leading cross-functional programs, he drives personalized engagement at scale and partners with leaders to deliver meaningful, measurable outcomes.

Karan sits on the Commercial Practice Leadership team at Inizio Ignite, Putnam and brings over a decade of experience advising leading US and European biopharmaceutical clients providing them with actionable recommendations for pipeline and in-line products. His core areas of focus are go-to-market strategy, customer engagement design, and portfolio strategy. Karan’s experience spans across a range of therapeutic areas, with recent engagements focused primarily on oncology, hematology, rare diseases, and neurology. Karan is an active contributor of industry thought-leadership focused on the evolution of customer engagement in the pharmaceutical industry and strategic implications for organizations. Prior to joining Putnam, Karan focused on R&D and Product Design at Vasoptic Medical, a clinical-stage med-tech start-up developing a novel imaging platform for early diagnosis of ophthalmic diseases. Karan holds a B.S. in Bioengineering from the University of Maryland, an M.Eng in Biomedical Engineering from Cornell University, and an MBA from London Business School.

Karen is an experienced life sciences executive with a background in both management consulting and internal consulting roles in the pharmaceutical industry for over 20 years. Her experience and expertise includes partnering with clients to bring their Commercial and Medical Excellence initiatives from strategy to action and connecting the dots across industry trends, best practices and innovative ways of working.

Karen Swords is a Senior Director and Head of Quantitative at Inizio Ignite, Research Partnership, where she leads quantitative research across global healthcare clients. She works closely with client teams to help shape brand, portfolio, and strategic decisions, bringing clarity to complex challenges through robust, commercially relevant insight. Her experience spans both discrete research and large-scale performance tracking programmes, where she provides an ongoing view of commercial performance and supports senior stakeholders in navigating complex, evolving markets. Karen is also responsible for how quantitative research is delivered across the business, focusing on improving ways of working, streamlining processes, and making practical use of evolving technologies to support efficient, consistent delivery and clear, decision-ready outputs. With over 20 years’ experience in healthcare research, Karen is known for her pragmatic approach, high standards, and collaborative style, helping clients and teams get the most from their data and make confident decisions.

With over 8 years of leadership experience, my focus is on combining commercial success with sustainable organizational development. I operate at the intersection of strategy, communication, and leadership to empower teams, drive transformation, and deliver measurable results.

Together with my team, I lead national and international projects that enhance market performance, strengthen partnerships, and create long-term value for our clients. My ambition is to generate sustainable impact through clear priorities, innovative approaches, and true collaboration.

Lori leads the Medical and Scientific Affairs Practice at Inizio Ignite, Putnam. She has deep experience across a broad range of therapeutic areas, and has supported numerous Medical Affairs organizations with asset development, brand planning and launch strategy, and implementation and impact. Lori is a member of the Inizio Advisory Executive AI Working Group and chairs Putnam’s AI Working Group. She is a contributing author of the MAPS GenAI white paper, a frequent speaker on AI in Medical Affairs, and has partnered with clients to design and implement bespoke AI solutions. She is also active in MAPS, serving as an AI Lead for the Insights Focus Area Working Group and as the Data Gap Identification Competency Lead. Prior to Putnam, Lori had a Medical Affairs strategy consultancy, built the Medical Affairs division at CDM and later became President. Earlier in her career she gained experience in medical education and MSL training at Bayer, and clinical research at the University of Minnesota. Lori holds an RPh from the University of Iowa, a PharmD from the University of Minnesota, and completed a postdoctoral fellowship in critical care and infectious diseases at the University of Minnesota.

Maaz advises leading biopharmaceutical and other life sciences clients in value, pricing and access strategy as well as commercial and other cross-functional strategic projects. He has extensive experience across therapeutic areas, including oncology, hematology, respiratory, and across therapeutic modalities, including gene therapies. His expertise spans new product development and indication planning decisions, value proposition development and evidence planning, go-to-market pricing and market access strategy, and stakeholder engagement and lifecycle management. In addition to his strategic consulting experience, he also has in-depth industry experience obtained via an extensive secondment with a client global access and value team supporting a multi-country product launch. Maaz earned his MSc in Management from the London School of Economics and graduated with a degree in Medicine from St George’s University of London. Prior to joining Putnam, Maaz held position of ascending responsibility in other strategic pricing and market access consultancy.

Madeleine Lacaille is VP of Global Strategic Accounts at Inizio Ignite, based in London. She partners with senior global leaders across top 20 pharma organisations, designing bespoke programs to support product commercialisation and brand success. Madeleine works closely with cross-functional experts from Ignite to unlock value across the product lifecycle, from early development through to mature brands and LOE navigation. Madeleine brings 8 year's of industry expereince and is known for building long‑term, trusted partnerships with some of the industry’s most complex global accounts. Madeleine holds a BSc from Durham University and a Diploma in Professional Digital Marketing.

Marc Yates is Senior VP of Business Development APAC at Inizio Ignite, bringing over four decades of experience in the market research industry. He has spent the past 28 years specializing in emerging pharmaceutical markets, including over 15 years living and working across Asia. Marc began his time in the region in Shanghai with a focus on China, before moving to Hong Kong to lead pan-Asian initiatives, and later to Singapore where he established the APAC regional hub for The Research Partnership. In 2012, he returned to London to set up the Emerging Markets Division. Marc is a sought-after speaker at global pharmaceutical conferences, where he shares actionable insights drawn from deep APAC expertise, and has authored numerous publications that shape industry thinking.

Mariah has deep experience in shaping pharma and life sciences strategy. As a Putnam leader, Mariah translates findings from both primary and secondary research into actionable strategy, providing her clients with not only accurate, comprehensive insights but also clearly articulated implications across a wide range of disease areas. She has in-depth understanding of considerations for enterprise and therapeutic area portfolio optimization / asset prioritization, pivotal clinical trial design, market access & contracting strategies, and launch strategy for innovative therapies across global markets. She joined Putnam in 2017 following completion of her PhD in Chemistry and Chemical Biology at Harvard University.

Mariia leads and coordinates health economic modelling projects, dedicated to development, validation and adaptation of cost-effectiveness and budget impact models, furtherly utilized for economic evaluations within a decision-making framework. Her area of expertise includes static and transmission dynamic modelling, as well as conceptualization and enhancement of analyses integrating extended value considerations, such as DCEAs. Mariia has a strong scientific background in pharmacology, microbiology and molecular biology, and analytical competence in several therapeutic areas, including infectious, cardiovascular, haematologic, metabolic, neurological disorders, and others.

Marine is a Principal at Inizio Ignite, Putnam with over 13 years of experience in Health Economics and Market Access consulting, with a strong focus on the French market. She is part of the HTA and Market Access team and has contributed to more than 50 French economic submissions (CEESP) across a wide range of therapeutic areas, including oncology, onco-haematology, neurology, dermatology, and rare diseases. Her expertise includes the development and adaptation of health economic models, critical appraisal of real-world evidence, and pragmatic literature reviews. She holds a PharmD and a MSc. in Public Health from the University of Lyon.

Mateusz has extensive (15 years) experience in quantitative synthesis of clinical data, including meta-analysis, network meta-analysis, and matching-adjusted indirect comparison, at both managerial and analytical levels. He is also experienced in statistical analyses on patient-level data. His areas of special interest include the methodology related to survival analysis and Bayesian modeling. In addition, he is an academic lecturer, teaching biostatistics and combinatorics, with the latter related to his former research area.

Matt Dalius is a Senior Director with over 20 years of transformation consulting experience, specializing in complex, global initiatives across the pharmaceutical industry. He brings deep expertise in program leadership, operating model design, and enterprise system integration, with a strong track record of aligning cross-functional stakeholders and delivering scalable, business-driven solutions. Matt has led large-scale transformations across 20+ markets, with a focus on commercial operations and global service model optimization. He currently serves as Vynamic's Organizational Effectiveness Co-Delivery Lead, Commercial Operations Domain Co-Lead, and Commercial IT Domain Specialist, where he helps shape delivery excellence and provides SME leadership across critical domains.

Maura Dee is a seasoned leader in the Inizio Ignite Launch Practice, serving as the Product Launch Delivery lead at Vynamic. With nearly two decades of experience in life sciences consulting and a proven track record of leading high performing teams and shaping launch strategies, Maura brings authentic leadership and operational expertise to drive launch excellence across clients. With over 16 years of experience at Vynamic working within Life Sciences, Maura is passionate about bringing her commercial and launch experience to bring new products to market faster and keeping the needs of the patients at the forefront. Maura has deep Oncology experience as well as US and Global Launch, Alliances, Patient Experience design and MLR process optimization

Meredith has helped provide strategic insights and recommendations to pharmaceutical and biotech clients across a wide range of therapeutic areas including, but not limited to, hematology / oncology, neurology, dermatology, and rare diseases. Her business engagements have also been expansive, including novel development strategy, commercial opportunity, competitive landscape and assessment, pricing strategy, and market access. Prior to joining Putnam in 2016, Meredith earned her BA in economics, with concentrations in finance and international trade, from Dartmouth College.

Michael leads a team that helps U.S. pharma and biotech teams with field personnel accelerate performance, providing insights and recommendations to enhance team alignment and customer engagement. Prior to joining STEM, Michael consulted, coached and trained for companies ranging from start-ups to global firms, across a wide variety of industries, and led pharmaceutical sales, marketing and new product commercialization teams. He also served in the U.S. Navy, conducting diving and explosive ordnance disposal operations in the U.S. and abroad. Michael has an MBA from Henley Business School and has completed executive education courses in Innovation Management (MIT Sloan School of Business), Finance Leadership (Harvard Business School) and International Management (Ashridge).

Michelle has been consulting in healthcare market research for more than 20 years. With expertise in both qualitative and quantitative research, she provides strategic insights for business objectives spanning the product life cycle. Throughout any engagement, Michelle strives to provide exceptional customer service, collaboration, and high-quality research and deliverables.

Mike is the AI, Innovation & Activation Lead at Inizio Ignite, where he focuses on building the internal capabilities, operating models, adoption frameworks, and innovation programming that enable Inizio - and clients - to get real value from data, digital, and artificial intelligence. Working across Inizio’s advisory businesses, he helps translate emerging technologies such as generative AI and advanced analytics into practical, scalable approaches that can be applied in client engagements. Mike brings deep experience spanning commercial data strategy, commercial operations, and technology enabled transformation across the life sciences and healthcare ecosystem. He is known for bridging strategy and execution - connecting business needs, data, and change management to modernize how organizations make decisions and work. In client contexts, Michael advises on AI readiness, use case prioritization, governance, and adoption, helping organizations move from experimentation to sustained impact.

Mike leads the Customer Experience consulting practice at Inizio Ignite. This includes a focus on omnichannel transformation, marketing, patient services, and digital engagement. Mike brings 16 years of digital and organizational transformation experience, serving multiple industries, with a focus in Life Sciences. He is also a frequent speaker at conferences, webinars, & podcasts.

Mindy McGrath is a Managing Director of Domain Specialization at Inizio Ignite, Vynamic, specializing in product launch, market access, and commercial strategy for life sciences organizations. She helps translate complex policy and market dynamics into actionable plans, partnering with senior leaders to drive performance. Mindy has experience across multiple therapeutic areas with prior roles at PwC and Bristol Myers Squibb. She is the host of the Trending Health podcast.